Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206603 | 1.00 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL764061 | 1.00 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL22034968 | 0.84 | POLB (0.43) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL22082567 | 0.84 | POLB (0.43) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL10223175 | 0.81 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL13721603 | 0.81 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL12788615 | 0.81 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL22034564 | 0.80 | OPRK1 (0.42) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL27906694 | 0.78 | POLB (0.76) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL27976413 | 0.78 | POLB (0.76) | POLBL3MBTL1EPHX2DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083472-A2 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085815-A1 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2023011597-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | Hepagene Therapeutics (HK) Limited (CN) | 2023-02-09 | — | — | WO | disclosed |
| CN-104818276-B | Single-stranded nucleic acid molecules for controlling gene expression | 株式会社博纳克 | 2020-12-11 | — | — | CN | disclosed |
| EP-2933333-B1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORP (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-20160108400-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2933333-A1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | Bonac Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| EP-2431466-B1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORP (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | POLB 1816/4885L3MBTL1 4882/4885EPHX2 347/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | POLB 1816/4885L3MBTL1 4882/4885EPHX2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.